All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter
First reported by thelundreport.org
Copay assistance is meant to defray patient drug costs. Some insurers keep it instead.

How Insurers Use Copay Accumulator Programs to Undermine Drug Assistance for Patients

This article investigates how health insurers use "copay accumulator" programs to prevent drug manufacturer copay assistance coupons from counting toward patients' deductibles and out-of-pocket maximums. Through the story of Larry Gruber, a patient with psoriatic arthritis who relied on an Enbrel coupon card for 16 years, the article explains how insurers have shifted to policies that pocket copay assistance funds while leaving patients with unexpected bills. It covers the financial impact on patients, the role of pharmacy benefit managers (PBMs), state-level bans in some states, stalled federal oversight, and the broader implications for healthcare affordability in the U.S.

Daniel Chang3h ago11 min readenNews
Read on truthout.org

Key quotes

For 16 years, Larry Gruber, a fitness coach from Wilton Manors, Florida, received a coupon card to help him pay for a psoriatic arthritis medication he needs that costs more than $7,700 a month.
Using the card, Gruber usually met that maximum by February, leaving his health insurance to fully cover his in-network medical costs and reducing his cost for the drug to $0 for
While some states ban insurers from using copay accumulator programs, oversight has stalled at the federal level.

From the article

While some states ban insurers from using copay accumulator programs, oversight has stalled at the federal level.
Continue reading on truthout.org

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.